Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Net Cash Flow (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Net Cash Flow data on record, last reported at $16.8 million in Q4 2021.

  • For Q4 2021, Net Cash Flow fell 85.11% year-over-year to $16.8 million; the TTM value through Dec 2021 reached -$22.4 million, down 111.4%, while the annual FY2025 figure was $214.3 million, 376.82% up from the prior year.
  • Net Cash Flow reached $16.8 million in Q4 2021 per COGT's latest filing, up from -$15.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $112.8 million in Q4 2020 and bottomed at -$15.2 million in Q3 2021.
  • Average Net Cash Flow over 4 years is $11.4 million, with a median of -$2.9 million recorded in 2018.
  • Peak YoY movement for Net Cash Flow: crashed 497.02% in 2019, then soared 1433.29% in 2020.
  • A 4-year view of Net Cash Flow shows it stood at $6.4 million in 2018, then crashed by 232.67% to -$8.5 million in 2019, then skyrocketed by 1433.29% to $112.8 million in 2020, then crashed by 85.11% to $16.8 million in 2021.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $16.8 million in Q4 2021, -$15.2 million in Q3 2021, and -$12.5 million in Q2 2021.